EHA 2021 | Translational and clinical advances in acute GVHD

Name: Translational and clinical advances in acute GVHD
Uploaded: 2021-06-07T00:00:00Z
Duration: 1 min 50 s
Description: John Koreth, MBBS, PhD, Dana-Farber Cancer Institute, Boston, MA, shares an update on the latest translational and clinical advances in the field of acute graft-versus-host disease (GvHD), in particular highlighting the potential future role of itolizumab in the frontline setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

John Koreth • 7 Jun 2021

EHA 2021

General Antibodies Itolizumab

John Koreth, MBBS, PhD, Dana-Farber Cancer Institute, Boston, MA, shares an update on the latest translational and clinical advances in the field of acute graft-versus-host disease (GvHD), in particular highlighting the potential future role of itolizumab in the frontline setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

John Koreth, MBBS, PhD, has received research support from Bristol Myers Squibb, Miltenyi, Clinigen, Amgen and Regeneron; has participated in advisory boards with Therakos, Cugene and Regeneron; and has participated in consultancy work with EMD Serono/Merck, Biolojic Design, Gentibio, Moderna Therapeutics and Equillium.